Status:
ACTIVE_NOT_RECRUITING
Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)
Lead Sponsor:
Scripps Whittier Diabetes Institute
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system i...
Detailed Description
There is strong evidence that poor glycemic control in the hospital is common. Given the known consequences of uncontrolled blood sugars during a hospitalization (e.g., infection, serious neurological...
Eligibility Criteria
Inclusion
- Documented previous or current Type 2 Diabetes (T2D) diagnosis as defined by either diagnosis in the chart or an HbA1c \> or = to 6.5% in the last 90 days
- Either on subcutaneous (SQ) insulin orders, or greater than two serum or Point of Care (POC) glucose \> or = 200 mg/dL in most recent 24 hours of admission
Exclusion
- Anticipated length of stay \< 24 hours;
- Current or anticipated ICU placement;
- Does not speak English or Spanish;
- Known allergy to adhesives;
- Current participation in any medication or device research study;
- Pregnant;
- Any other condition that Multiple Principal Investigator (MPI) Philis-Tsimikas or the attending physician deems contraindicated
Key Trial Info
Start Date :
April 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2026
Estimated Enrollment :
518 Patients enrolled
Trial Details
Trial ID
NCT05307237
Start Date
April 19 2022
End Date
January 31 2026
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Mercy Hospital
Chula Vista, California, United States, 91910